Effects of acupuncture for prehypertension & stage 1 hypertension in postmenopausal wome
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0001259
- Lead Sponsor
- Korea Institute of Oriental Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 56
1. Women aged 45 to 65 years
2. Menstruation ended 1 year or longer prior to the study
3. Resting blood pressure measured during screening is in the prehypertension stage (systolic blood pressure (SBP) of 120–139 mmHg or diastolic blood pressure (DBP) of 80–89 mmHg) or at stage 1 hypertension (SBP of 140–159 mmHg or DBP of 90–99 mmHg)
4. Provide consent to participate in this trial and sign an informed consent statement after listening to a clear explanation of the purpose and characteristics of this clinical trial
1. Received antihypertensive drugs, herbal medication or functional food used for hypertension, herbal tea such as persimmon leaf tea within the past 1 months
2. Received hormone therapy, such as estrogen or progestin, herbal medication or functional food used for involutional disorder in the past 1 month
3. History of secondary hypertension or are suspected of secondary hypertension (for example, coarctation of the aorta, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing’s syndrome, polycystic renal disease, hyperthyroidism
4. Orthostatic hypotension and accompanying symptoms
5. Uncontrolled diabetes mellitus
6. Severe heart disease, ischemic heart disease during the recent 6 months (angina pectoris, myocardial infarction), or peripheral vascular disease, or have received percutaneous transluminal coronary angioplasty or a coronary artery bypass graft
7. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortostenosis, or hemodynamically significant aortic or mitral valve stricture
8. Severe cerebrovascular disease, or have experienced a cerebral infarction or cerebral hemorrhage within the past 6 months
9. Moderate or malignant retinosis, retinal hemorrhage, visual disturbance, or retinal microaneurysm within the past 6 months
10. Consumptive disease (tuberculosis, malignant tumors) or autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, dermatomyositis, systemic sclerosis, or thyroiditis)
11. Clinically significant kidney or liver disease
12. Confirmed or suspected history of drug or alcohol abuse
13. Chronic inflammatory conditions that require chronic anti-inflammatory treatment
14. Currently participating in other clinical trials
15. Currently an inmate at a group facility, such as a social welfare institution
16. Did not provide informed consent
17. Anyone considered inappropriate for participating in this trial by the clinical trial conductors
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method